INmuneBIO XPRO-1595-AD-OLE

Drug Development Trials

About the trial

An Open Label Extension of Xpro1595 in patients with Alzheimer’s Disease (AD) or Mild Cognitive Impairment (MCI) due to AD that have completed a Phase 2 study with Xpro1595.